Denali Therapeutics Inc. (DNLI) Misses Q1 EPS by 8c

Denali Therapeutics Inc. (NASDAQ: DNLI) reported Q1 EPS of ($0.78), $0.08 worse than the analyst estimate of ($0.70).

For earnings history and earnings-related data on Denali Therapeutics Inc. (DNLI) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Lakeland Industries qualifies Vietnam cleanroom for critical environment output
• Baidu slips as Q2 results miss estimates despite growth in AI cloud business